English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219369
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1)

AuthorsKoumantou, Despoina; Barnea, Eilon; Martín-Esteban, Adrián ; Maben, Zachary; Papakyriakou, Athanasios; Mpakali, Anastasia; Kokkala, Paraskev; Pratsinis, Harris; Geogiadis, Dimitris; Stern, Lawrence J; Admon, Arie; Stratikos, Efstratios
KeywordsInhibitor
Aminopeptidase
MHC
Proteomics
Melanoma
Enzyme
Issue Date20-Jun-2019
PublisherSpringer
CitationCancer Immunology, Immunotherapy (2019)
AbstractThe efficacy of cancer immunotherapy, including treatment with immune-checkpoint inhibitors, often is limited by ineffective presentation of antigenic peptides that elicit T-cell-mediated anti-tumor cytotoxic responses. Manipulation of antigen presentation pathways is an emerging approach for enhancing the immunogenicity of tumors in immunotherapy settings. ER aminopeptidase 1 (ERAP1) is an intracellular enzyme that trims peptides as part of the system that generates peptides for binding to MHC class I molecules (MHC-I). We hypothesized that pharmacological inhibition of ERAP1 in cells could regulate the cellular immunopeptidome. To test this hypothesis, we treated A375 melanoma cells with a recently developed potent ERAP1 inhibitor and analyzed the presented MHC-I peptide repertoire by isolating MHC-I, eluting bound peptides, and identifying them using capillary chromatography and tandem mass spectrometry (LC-MS/MS). Although the inhibitor did not reduce cell-surface MHC-I expression, it induced qualitative and quantitative changes in the presented peptidomes. Specifically, inhibitor treatment altered presentation of about half of the total 3204 identified peptides, including about one third of the peptides predicted to bind tightly to MHC-I. Inhibitor treatment altered the length distribution of eluted peptides without change in the basic binding motifs. Surprisingly, inhibitor treatment enhanced the average predicted MHC-I binding affinity, by reducing presentation of sub-optimal long peptides and increasing presentation of many high-affinity 9–12mers, suggesting that baseline ERAP1 activity in this cell line is destructive for many potential epitopes. Our results suggest that chemical inhibition of ERAP1 may be a viable approach for manipulating the immunopeptidome of cancer.
Publisher version (URL)http://dx.doi.org/10.1007/s00262-019-02358-0
URIhttp://hdl.handle.net/10261/219369
DOIhttp://dx.doi.org/10.1007/s00262-019-02358-0
Identifiersdoi: 10.1007/s00262-019-02358-0
issn: 1432-0851
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Martín-EstebanA_EditingtheImmunopeptidome.pdf2,86 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.